IP Verse

Immunoactivating Antigen-Binding Molecule - EP3130606

The patent EP3130606 was granted to Chugai Seiyaku Kabushiki Kaisha on Oct 13, 2021. The application was originally filed on Apr 7, 2015 under application number EP15776419A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3130606

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP15776419A
Filing Date
Apr 7, 2015
Status
Granted And Under Opposition
Sep 10, 2021
Grant Date
Oct 13, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

J A KEMPJul 13, 2022J A KEMPADMISSIBLE
THOMANNJul 13, 2022-ADMISSIBLE

Patent Citations (30) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2005092927
EXAMINATIONWO2011039126
INTERNATIONAL-SEARCH-REPORTJP2012224631
INTERNATIONAL-SEARCH-REPORTJP2012515556
INTERNATIONAL-SEARCH-REPORTWO2012115241
INTERNATIONAL-SEARCH-REPORTWO2012175751
INTERNATIONAL-SEARCH-REPORTWO2013070468
OPPOSITIONEP1272647
OPPOSITIONEP2647707
OPPOSITIONEP3130606
OPPOSITIONWO0177342
OPPOSITIONWO2005092927
OPPOSITIONWO2006074399
OPPOSITIONWO2010085682
OPPOSITIONWO2011039126
OPPOSITIONWO2012073985
OPPOSITIONWO2012095412
OPPOSITIONWO2012175751
OPPOSITIONWO2015103072
OPPOSITIONWO2015156268
OPPOSITIONWO9961057
OTHEREP2543730
OTHERJP2014078457
OTHERUS2012201746
OTHERUS5648260
OTHERWO2011108714
OTHERWO2012088302
OTHERWO2014116846
SEARCHWO2012095412
SEARCHWO2012175751

Non-Patent Literature (NPL) Citations (53) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- MELERO I ET AL, "Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 29, no. 8, doi:10.1016/J.TIPS.2008.05.005, ISSN 0165-6147, (20080801), pages 383 - 390, (20080701), XP027070050
OPPOSITION- BERENBAUM, "Synergy, additivism and antagonism in immunosuppression, A Critical Review", Clin. Exp. Immunol, (19770000), vol. 28, pages 1 - 18, XP055363834-
OPPOSITION- Declaration of Prof. Ignacio Melero, MD, PhD-
OPPOSITION- Decl. of Prof. K Chester 4 Dec 2023-
OPPOSITION- DUBROT, J. et al., "Treatment with anti- CD 137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ", Cancer Immunol. Immunother., (20100000), vol. 59, pages 1223 - 1233, XP019842192-
OPPOSITION- Experimental Results-
OPPOSITION- Janeway Charles A., Paul Travers, Mark Walport, Mark J. Shlomchik, "The Humoral Immune Responce", Immuno Biology, the immune system in health and disease, 6th Edition, Garland Science, (20050101), page 400, XP093118378-
OPPOSITION- SCHABOWSKY, R-H. et al., "A novel form of 4-1 BBL has better immunomodulatory activity than an agonistic anti-4-1 BB Ab without Ab-associated severe toxicity", Vaccine, (20090000), vol. 28, pages 512 - 522, XP026791390-
OPPOSITION- Seimetz, D. ; Lindhofer, H. ; Bokemeyer, C., "Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy", Cancer Treatment Reviews, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20101001), vol. 36, no. 6, ISSN 0305-7372, pages 458 - 467, XP027256157-
OPPOSITION- Strohl William R., Lila M. Strohl, "Bispecific antibodies based on IgGs", THERAPEUTIC ANTIBODY ENGINEERING, CURRENT AND FUTURE ADVANCES DRIVING THE STRONGEST GROWTH AREA IN THE PHARMACEUTICAL INDUSTRY, Woodhead Publishing series in Biomedicine: Number 11, (20120101), pages 308 - 320, XP093118395-
OPPOSITION- WINES B D et al., "The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors Fc[gamma]RI and Fc[gamma]RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A", The Journal of Immunology, US , (20000515), vol. 164, no. 10, ISSN 0022-1767, pages 5313 - 5318, XP002381581-
OPPOSITION- BOLT S., ET AL., "THE GENERATION OF A HUMANIZED, NON-MITOGENIC CD3 MONOCLONAL ANTIBODY WHICH RETAINS IN VIRTO IMMUNUSUPPRESSIVE PROPERTIES.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19930201), vol. 23., no. 02., doi:10.1002/eji.1830230216, ISSN 0014-2980, pages 403 - 410., XP000561698
OPPOSITION- Markus M. Heiss et al, "The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial", International Journal of Cancer, Union Internationale Centre le Cancer., (20101101), vol. 127, no. 9, doi:10.1002/ijc.25423, ISSN 00207136, pages 2209 - 2221, XP055004724
OPPOSITION- Mezzanzanica Delia, Canevari, Silvana & Colnaghi, Maria I. , "Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic", Int J Clin Lab Res, (19920101), vol. 21, doi:10.1007/BF02591636, pages 159 - 164, XP055946494
OPPOSITION- Christian Brandl et al., "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", Cancer Immunology, Berlin, DE , (20070220), vol. 56, no. 10, doi:10.1007/s00262-007-0298-z, ISSN 1432-0851, pages 1551 - 1563, XP019539092
OPPOSITION- SEBASTIAN et al., "Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti- CD 3): a phase I study", Cancer Immunol Immunother, (20070000), vol. 56, doi:10.1007/s00262-007-0310-7, pages 1637 - 1644, XP019539101
OPPOSITION- PRESTA, "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function", Advanced Drug Delivery Reviews, (20060000), vol. 58, doi:10.1016/j.addr.2006.01.026, pages 640 - 656, XP024892146
OPPOSITION- WEON, J. L. et al., "The MAGE protein family and cancer", Current Opinion in Cell Biology, (20150000), vol. 37, doi:10.1016/j.ceb.2015.08.002, pages 1 - 8, XP029343219
OPPOSITION- STROHL, W. R., "Optimization of Fc-mediated effector functions of monoclonal antibodies", Current Opinion in Biotechnology, (20090000), vol. 20, no. 6, doi:10.1016/j.copbio.2009.10.011, pages 685 - 691, XP026778879
OPPOSITION- Reichert J M, Dhimolea E., "The future of antibodies as cancer drugs.", Drug Discovery Today, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20120901), vol. 17, no. 17-18, doi:10.1016/j.drudis.2012.04.006, ISSN 1359-6446, pages 954 - 963, XP002713827
OPPOSITION- WENT, P. T. et al., "Frequent EpCam Protein Expression in Human Carcinomas", Human Pathology, (20040000), vol. 35, doi:10.1016/S0046-8177(03)00502-1, pages 122 - 128, XP002592037
OPPOSITION- PASTOR et al., "Targeting 4-1BB Costimulation to Disseminated Tumor Lesions with Bi- specific Oligonucleotide Aptamers", Molecular Therapy, (20110000), vol. 19, doi:10.1038/mt.2011.145, pages 1878 - 1886, XP008150757
OPPOSITION- PASTOR, F. et al., "Targeting 4-1 BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers", Molecular Therapy, (20110000), vol. 19, no. 10, doi:10.1038/mt.2011.145, pages 1878 - 1886, XP008150757
OPPOSITION- WU ANNA M, SENTER P D, "Arming antibodies: prospects and challenges for immunoconjugates.", Nature Biotechnology, Nature Publishing Group US, New York, New York, vol. 23, no. 9, doi:10.1038/nbt1141, ISSN 1087-0156, pages 1137 - 1146, XP002509773
OPPOSITION- Andrew M. Scott, Jedd D. Wolchok, Lloyd J. Old, "Antibody therapy of cancer", Nature Reviews Cancer, Nature Pub. Group, (20120101), vol. 12, no. 4, doi:10.1038/nrc3236, ISSN 1474175X, pages 278 - 287, XP055023837
OPPOSITION- HOGARTH et al., "Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond", Nature Reviews Drug Discovery, (20120000), vol. 11, doi:10.1038/nrd2909, pages 311 - 331, XP002716468
OPPOSITION- ROOPENIAN DERRY C, ET AL, "FcRn: the neonatal Fc receptor comes of age.", Nature Reviews Immunology, Nature Publishing Group UK, London, London, (20070901), vol. 7, no. 9, doi:10.1038/NRI2155, ISSN 1474-1733, pages 715 - 725, XP002510057
OPPOSITION- Labrijn Aran F. et al, "Bispecific antibodies: a mechanistic review of the pipeline", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , (20190607), vol. 18, no. 8, doi:10.1038/s41573-019-0028-1, ISSN 1474-1776, pages 585 - 608, XP036848551
OPPOSITION- ASCIERTO, P. A. et al., "Clinical Experiences With Anti- CD 137 and Anti-PD1 Therapeutic Antibodies", Seminars in Oncology, (20100000), vol. 37, no. 5, doi:10.1053/j.seminoncol.2010.09.008, pages 508 - 516, XP008175440
OPPOSITION- LAZAR G A ET AL, "Engineered antibody Fc variants with enhanced effector function", Proceedings of the National Academy of Sciences, (20060301), vol. 103, no. 11, doi:10.1073/pnas.0508123103, ISSN 0027-8424, pages 4005 - 4010, XP002403708
OPPOSITION- Li Fubin, Ravetch Jeffrey V., "Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement", Proceedings of the National Academy of Sciences, (20120703), vol. 109, no. 27, doi:10.1073/pnas.1208698109, ISSN 0027-8424, pages 10966 - 10971, XP055946492
OPPOSITION- Li Fubin, Ravetch Jeffrey V., "Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo", Proceedings of the National Academy of Sciences, (20131126), vol. 110, no. 48, doi:10.1073/pnas.1319502110, ISSN 0027-8424, pages 19501 - 19506, XP055946487
OPPOSITION- SHIELDS et al., "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", Journal of Biological Chemistry, US , (20010302), vol. 276, no. 9, doi:10.1074/jbc.M009483200, ISSN 0021-9258, pages 6591 - 6604, XP002271092
OPPOSITION- MULLER, D. et al., "A Novel Antibody-4-1 BBL Fusion Protein for Targeted Costimulation in Cancer Immunotherapy", Journal of Immunotherapy., (20080000), vol. 31, no. 8, doi:10.1097/CJI.0b013e31818353e9, pages 714 - 722, XP009500125
OPPOSITION- Ilse Houtenbos et al., "The novel bispecific diabody αCD40/αCD28 strengthens leukaemic dendritic cell‐induced T‐cell reactivity", British Journal of Haematology, Hoboken, USA, (20080628), vol. 142, no. 2, doi:10.1111/j.1365-2141.2008.06990.x, ISSN 0007-1048, pages 273 - 283, XP071055621
OPPOSITION- Alexei V. Salnikov et al, "Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, UNIVERSITY PRESS CAROL DAVILA, BUCHAREST, RO, RO , (20090901), vol. 13, no. 9b, doi:10.1111/j.1582-4934.2009.00723.x, ISSN 1582-1838, pages 4023 - 4033, XP055606247
OPPOSITION- M. X. Sliwkowski, Mellman I., "Antibody Therapeutics in Cancer", Science, American Association for the Advancement of Science, (20130913), vol. 341, no. 6151, doi:10.1126/science.1241145, ISSN 00368075, pages 1192 - 1198, XP055079418
OPPOSITION- BREMER, E., "Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy", ISRN Oncology, (20130000), vol. 2013, doi:10.1155/2013/371854, XP055360248
OPPOSITION- B. Schlereth et al, "Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct", Cancer research, American Association for Cancer Research, US, US, (20050401), vol. 65, no. 7, doi:10.1158/0008-5472.CAN-04-2637, ISSN 0008-5472, pages 2882 - 2889, XP055363255
OPPOSITION- M. Amann et al, "Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3", Cancer research, American Association for Cancer Research, US, US, (20080101), vol. 68, no. 1, doi:10.1158/0008-5472.CAN-07-2182, ISSN 0008-5472, pages 143 - 151, XP055287977
OPPOSITION- A. Burges et al, "Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A Phase I/II Study", Clinical Cancer Research, Association for Cancer Research, (20070701), vol. 13, no. 13, doi:10.1158/1078-0432.CCR-06-2769, ISSN 10780432, pages 3899 - 3905, XP055167636
OPPOSITION- MELERO, I. et al., "Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells", Clinical Cancer Research, (20130000), vol. 19, no. 5, doi:10.1158/1078-0432.CCR-12-2065, pages 1044 - 1053, XP055132838
OPPOSITION- GILBOA, E. et al., "Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors", Clinical Cancer Research, (20120000), vol. 19, no. 5, doi:10.1158/1078-0432.CCR-12-2067, pages 1054 - 1062, XP055553699
OPPOSITION- GILBOA et al., "Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors", Clin Cancer Res, (20130000), vol. 19, doi:10.1158/1078-0432.CCR-12-2067, pages 1054 - 1062, XP055553699
OPPOSITION- RICHMAN et al., "Role of Crosslinking for Agonistic CD 40 Monoclonal Antibodies as Immune Therapy of Cancer", Cancer Immunol Res, (20130000), vol. 2, doi:10.1158/2326-6066.CIR-13-0152, pages 19 - 26, XP055393427
OPPOSITION- HOUOT R. et al., "Therapeutic effect ofCD137 immunomodulation in lymphoma and its enhancement by Treg depletion", Blood, (20090000), vol. 114, no. 16, doi:10.1182/blood-2009-05-223958, pages 3431 - 3438, XP055034665
OPPOSITION- "CHAPTER 10: Antibody Fc engineering for optimal antibody performance", William R Strohl, Lila M Strohl, Therapeutic antibody engineering (in: Woodhead Publishing Series in Biomedicine), WP, Woodhead Publishing , (20120101), vol. 11, pages 225 - 249, doi:10.1533/9781908818096.225, ISBN 978-1-908818-09-6, XP009181736
OPPOSITION- RATH et al., "Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics", Crit Rev Biotechnol, vol. 35, doi:10.3109/07388551.2013.834293, (20131022), pages 235 - 254, XP055597699
OPPOSITION- Wei Jing, Yang Yueyao, Wang Gang, Liu Ming, "Current landscape and future directions of bispecific antibodies in cancer immunotherapy", Frontiers in Immunology, Frontiers Media, Lausanne, CH, Lausanne, CH , (20221028), vol. 13, doi:10.3389/fimmu.2022.1035276, ISSN 1664-3224, page 1035276, XP093147116
OPPOSITION- Stamova Slava et al, "Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs", Antibodies, M D P I AG, CH, CH , (20120718), vol. 1, no. 2, doi:10.3390/antib1020172, ISSN 2073-4468, pages 172 - 198, XP055883357
OPPOSITION- Janice M. Reichert null, "Antibodies to watch in 2014", mAbs, (2014), vol. 6, doi:10.4161/mabs.29282, XP055153796
SEARCH- PASTOR FERNANDO ET AL, "Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers", MOLECULAR THERAPY, ACADEMIC PRESS, US, (20111001), vol. 19, no. 10, doi:10.1038/MT.2011.145, ISSN 1525-0016, pages 1878 - 1886, XP008150757 [A] 1-13 * the whole document *
SEARCH- MUELLER DAFNE ET AL, "A novel antibody-4-1 BBL fusion protein for targeted costimulation in cancer immunotherapy", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINGS INC, US, (20080930), vol. 31, no. 8, doi:10.1097/CJI.0B013E31818353E9, ISSN 1524-9557, pages 714 - 722, XP009500125 [X] 1,3-5,7-13 * the whole document * [Y] 2,6

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents